hs-CRP

In type 2 diabetes patients with coronary artery disease, suPAR levels remain unchanged despite treatment and independently predict adverse cardiovascular events beyond hs-CRP, highlighting suPAR's potential in identifying treatment-resistant inflammation and refining cardiovascular risk stratification.